Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD)

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rocatinlimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development

    • Most Recent Events

    • 12 Mar 2024 Results assessing whether rocatinlimab improved pNRS and EASI by Week 2; improvements continued and were maintained off-treatment until the end of study, presented at the American Academy of Dermatology annual Meeting 2024
    • 14 Feb 2024 According to the Kyowa Kirin Media Release, data from this study will be presented at the upcoming American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego from March 8-12, 2024.
    • 11 Oct 2023 According to the Kyowa Kirin Media Release, the company announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083),in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top